Vyne Therapeutics Stock Analysis

Vyne Stock Analysis Notes

About 59.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.44. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vyne Therapeutics recorded a loss per share of 2.72. The entity had not issued any dividends in recent years. The firm had 1:18 split on the 13th of February 2023. VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Vyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more information please call David Domzalski at 800 775 7936 or visit https://www.vynetherapeutics.com.

Vyne Therapeutics Investment Alerts

Vyne Therapeutics Upcoming and Recent Events

Vyne Largest EPS Surprises

View All Earnings Estimates

Vyne Therapeutics Thematic Classifications

Vyne Stock Institutional Investors

Note, although Vyne Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vyne Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vyne Therapeutics's market, we take the total number of its shares issued and multiply it by Vyne Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Vyne Profitablity

Management Efficiency

Vyne Therapeutics has return on total asset (ROA) of (0.2642) % which means that it has lost $0.2642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.464) %, meaning that it created substantial loss on money invested by shareholders. Vyne Therapeutics' management efficiency ratios could be used to measure how well Vyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.34. At present, Vyne Therapeutics' Net Tangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Total Current Assets are forecasted to decline to about 78.4 M.

Technical Drivers

As of the 25th of April, Vyne Therapeutics has the Risk Adjusted Performance of 0.0775, semi deviation of 3.26, and Coefficient Of Variation of 906.14. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vyne Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Vyne Therapeutics, which can be compared to its competition. Please validate Vyne Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Vyne Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 2.32 per share. Please also confirm Vyne Therapeutics total risk alpha, which is currently at (0.08) to double-check the company can sustain itself at a future point.

Vyne Therapeutics Price Movement Analysis

Vyne Therapeutics Insider Trading Activities

Vyne Therapeutics Predictive Daily Indicators

Vyne Therapeutics Corporate Filings

Vyne Therapeutics Forecast Models

Vyne Therapeutics' time-series forecasting models are one of many Vyne Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vyne Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vyne Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vyne shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vyne Therapeutics. By using and applying Vyne Stock analysis, traders can create a robust methodology for identifying Vyne entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vyne analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vyne analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Vyne Therapeutics stock analysis indicators help investors evaluate how Vyne Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vyne Therapeutics shares will generate the highest return on investment. By understating and applying Vyne Therapeutics stock analysis, traders can identify Vyne Therapeutics position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Vyne Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.